Abstract

Inflammatory breast cancer (IBC) is a rare and aggressive subtype of breast cancer characterized by rapid progression and a poor prognosis. This review examines the disparities in diagnosis and treatment faced by patients with IBC, emphasizing the influence of socio-economic, racial, and geographic factors. Despite advancements in medical knowledge, significant barriers persist, including a lack of awareness among healthcare providers, limited access to timely diagnosis, and unequal treatment options. Patients from marginalized communities often experience delayed diagnoses and are underrepresented in clinical trials, further exacerbating health inequities. This article highlights the need for targeted educational initiatives, policy changes, and strategies to enhance clinical trial participation to address these disparities. By promoting equity in care, we can improve outcomes for all patients affected by IBC.